Replies to post #583245 on NorthWest Biotherapeutics Inc (NWBO)

[jman4956]

Thank you.

[hoffmann6383]

Thanks for clearing this up Lykiri!

[sentiment_stocks]

Some of those 170 patients (maybe 90ish) likely included the Expanded Access Protocol (EAP) trial patients... those who did not enter the main arm of the trial but had vaccine made for them. These would have been whose patients who had rapid or psPD from chemo/rad, not enough vaccine material to make 5+ doses, and other reasons. It would have probably also included the info arm patients (50ish?).

These patients date back to October 2019, and so would not include any new compassionate use or specials patients since then.

[dstock07734]

Lykiri,

Thanks for the great post. I have been looking for the number of patients treated under compassionate use program or expanded access program.

170 is just the number up to 2019. I cannot imagine what is the number nowadays.

[ae kusterer]

Lykiri: "Northwest Biotherapeutics has treated over 170 glioblastoma patients, and non-glioblastoma patients, under compassionate use."; I assume this )nwbo'stotal compassionate use count of patients) includes all of Ashkan's patients.right or wrong?

Re: JerryCampbell post# 583145

Wednesday, April 05, 2023 6:52:32 PM

Post#
583245
of 583280
The Fourth Biennial World Summit of Brain Tumour Patient Advocates at the National Institutes of Health (NIH) in Bethesda, Maryland, October 9 to 12, 2019.
Plenary session 10 at the IBTA World Summit
Access to Therapies (compassionate use, off-label use, regulatory approval and HTA)
Panellists: Dr. Mark Gilbert, Linda Powers, Irina Odnoletkova, Suzanne Demko (FDA), David Jenkinsson.
Outside of their current trial for a dendritic cell immunotherapy, Northwest Biotherapeutics has treated over 170 glioblastoma patients, and non-glioblastoma patients, under compassionate use. Linda believes that patients need more say in decision making and more access to new treatments through compassionate use. Linda explained that Northwest Biotherapeutics collects all the data from their compassionate use patients. Patients groups can help enormously by increasing contributions of compassionate use data to data registries.


https://issuu.com/ibta-org/docs/ibta_magazine_2020

15 Likes

[ae kusterer]

Lykiri: I was told on 5/10/22, at NYAS, that as of that moment, Dr.Ashkan had treated 200-250 in the U. K. Specials program. Hope that helps.

Re: JerryCampbell post# 583145

Wednesday, April 05, 2023 6:52:32 PM

Post#
583245
of 583308
The Fourth Biennial World Summit of Brain Tumour Patient Advocates at the National Institutes of Health (NIH) in Bethesda, Maryland, October 9 to 12, 2019.
Plenary session 10 at the IBTA World Summit
Access to Therapies (compassionate use, off-label use, regulatory approval and HTA)
Panellists: Dr. Mark Gilbert, Linda Powers, Irina Odnoletkova, Suzanne Demko (FDA), David Jenkinsson.
Outside of their current trial for a dendritic cell immunotherapy, Northwest Biotherapeutics has treated over 170 glioblastoma patients, and non-glioblastoma patients, under compassionate use. Linda believes that patients need more say in decision making and more access to new treatments through compassionate use. Linda explained that Northwest Biotherapeutics collects all the data from their compassionate use patients. Patients groups can help enormously by increasing contributions of compassionate use data to data registries.


https://issuu.com/ibta-org/docs/ibta_magazine_2020

[eagle8]

Fantastic detective work and information Lykiri.
Thank you!

Best.

[TTsr]

Wow TY… “had treated 170 gbm and NON GBM patients”. That NON is HUGE!!